CONCISE REPORT

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study

Atul Deodhar,1 Jürgen Braun,2 Robert D Inman,3 Désirée van der Heijde,4 Yiying Zhou,5 Stephen Xu,5 Chenglong Han,6 Benjamin Hsu7

ABSTRACT

Objective Asses golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS).

Methods 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed over to 50 mg. Blinded active therapy continued through week 104; from week 104 to week 252, the golimumab dose could be adjusted. Intent-to-treat and observed efficacy data were assessed by randomised treatment groups.

Results At week 256, and with >4.5 years of golimumab, overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) and ASAS40 response rates were 66.0% (235/356) and 57.0% (203/356), respectively; Bath AS Disease Activity Index 50% improvement response was 55.9% (199/356). Observed response rates among the 255 (72%) patients who continued golimumab through week 252 were consistent, albeit somewhat higher. Among patients who increased golimumab from 50 to 100 mg, 60.6% (20/33) and 44.7% (17/38) achieved ASAS20/ASAS40 responses, respectively, following ≥2 consecutive doses of golimumab 100 mg. Golimumab safety through week 268 was similar to that through week 24 regardless of dose.

Conclusions Clinical improvements observed in patients treated with golimumab through week 24 were sustained through week 256 (5 years). Long-term golimumab safety is consistent with that of other established tumour-necrosis-factor-antagonists.

Trial registration number ClinicalTrials.gov: NCT00265083.

Golimumab, a human monoclonal antibody to tumour necrosis factor (TNF)-α that is administered subcutaneously every 4 weeks, is approved for treating active ankylosing spondylitis (AS). We previously reported results of the double-blind, randomised, placebo-controlled, Phase 3 GO-RAISE study, in which golimumab was evaluated in patients with active AS, through week 241 and week 1042 and now report findings through the completion of the 5-year GO-RAISE trial.

PATIENTS AND METHODS

Details of GO-RAISE patient eligibility criteria and study design have been reported1 and are summarised in the online supplement. Details of analyses specific to this 5-year report are also provided in the online supplement.3–12

RESULTS

Patient disposition/characteristics and concomitant medications

Among the 356 randomised patients, 355 received study treatment (figure 1). Baseline patient and disease characteristics, as well as patient disposition through week 241 and week 104,2 have been reported.

At week 16, 41 of 78 (52.6%) and 25 of 137 (18.2%) patients in Groups 1 and 2, respectively, had <20% improvement in total back pain and morning stiffness and entered early escape. Among the 335 treated patients, 101 (28.5%) discontinued study agent through week 252 (figure 1). Among patients who discontinued study agent due to adverse events (AEs), being lost to follow-up, or due to ‘other’ reasons, 51% achieved an Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response at the visit preceding discontinuation, versus 15% of patients who discontinued due to unsatisfactory therapeutic effect.

The proportion of patients using non-steroidal anti-inflammatory drugs declined from baseline to week 268 from 90% to 74% while that using disease-modifying antirheumatic drugs was relatively stable (32% to 36%) during the study.

Efficacy

Assessment in SpondyloArthritis international Society (ASAS) responses

Results of intent-to-treat (ITT) analyses indicated that 220/356 (61.8%) and 166/356 (46.6%) patients achieved ASAS20 response and/or ≥40% improvement (ASAS40) improvement, respectively, at week 24. At week 256, 233/356 (66.0%; 95% CI 61.1% to 70.9%) and 203/356 (57.0%; 95% CI 51.9% to 62.1%) patients achieved ASAS20 and/or ASAS40 response, respectively (figure 2A, B). ASAS partial remission (value <2 in each ASAS domain) was achieved by 121/356 (34.0%; 95% CI 29.1% to 38.9%) patients treated with golimumab at week 256 (figure 2C). Response rates were consistent, albeit somewhat higher, when assessed using observed data among patients who did not discontinue study participation by week 24 (see online supplementary figure S1A–C).

Based on observed data, 54 patients escalated the golimumab dose from 50 mg to 100 mg during the
While 21 (38.9%) and 16 (29.6%) of these patients, respectively, achieved an ASAS20 or ASAS40 response before dose escalation, 33 and 38 patients, respectively, had not. Among these latter patients, 60.6% (20/33) achieved ASAS20 and 44.7% (17/38) achieved ASAS40 responses following ≥2 consecutive doses of golimumab 100 mg. Additional clinical findings are reported in the online supplement.

Health-related quality of life (HRQoL)
Mean changes from baseline in the physical component summary and mental component summary scores of the 36-item Short Form health survey indicated improvements in patients’ HRQoL were sustained with up to 5 years of golimumab treatment (see online supplementary table S1). When assessed using ITT analyses, 93/356 (26.1%; 95% CI 21.5% to 30.7%) and 180/356 (50.6%; 95% CI 45.4% to 55.8%) had achieved 36-item Short Form health survey physical component summary and mental component summary scores ≥50, respectively, at week 256 (see online supplementary table S1). Findings were consistent with observed data (data not shown).

Antibodies to golimumab
Antibody-to-golimumab findings are reported in the online supplement.

Safety
Safety results through week 241 and week 1042 were previously reported. Reported AEs from baseline through week 268 are...
summarised in Table 1 for patients who received \( \geq 1 \) dose of golimumab through the first use of commercial biologics.

Through week 268, serious AEs were reported for 72 (20.4%) patients treated with golimumab (Table 1), most commonly osteoarthritis requiring hospitalisation (2.0%), pneumonia (1.1%), worsening of AS (1.1%), and depression (1.1%). No increases in serious AEs were observed in successive years of golimumab treatment (see online supplementary Table S2).

One (0.3%) patient, randomised to receive golimumab 50 mg, died from pancreatic cancer. This patient had also developed lymphoma after 3 years in the study and was receiving chemotherapy when the pancreatic cancer was discovered. The overall incidence of death for patients treated with golimumab was 0.07/100 patient-years (95% CI 0.00 to 0.38), with no difference observed between doses (Table 1). In addition to the malignancies in one patient described above, two patients treated with golimumab had non-melanoma skin cancer (NMSC) through week 268, including one (1.3%) patient each receiving golimumab 50 mg and 100 mg and golimumab 100 mg only. For lymphoma, NMSC, other malignancies and all malignancies, the incidences per 100 patient-years did not appear to be dose-related (Table 1). In addition to the malignancies in one patient described above, two patients treated with golimumab had non-melanoma skin cancer (NMSC) through week 268, including one (1.3%) patient each receiving golimumab 50 mg and 100 mg and golimumab 100 mg only. For lymphoma, NMSC, other malignancies and all malignancies, the incidences per 100 patient-years did not appear to be dose-related (Table 1). Similarly, the incidences of malignancies other than NMSC (excluded from the Surveillance, Epidemiology, and End Results database) were not elevated relative to those expected in the USA population (Table 1). No overall increase in the incidence of malignancies was observed in successive years of golimumab treatment (see online supplementary Table S2).

Serious infections were reported for 5.9% (21/353) of patients treated with golimumab through week 268. Pneumonia (four (1.1%) patients) was the only serious infection reported by more than one patient. The incidence of serious infections among patients receiving golimumab 100 mg appeared higher than for patients receiving only golimumab 50 mg (Table 1). No increase in serious infections was observed, however, in successive years of golimumab treatment (see online supplementary Table S2).

**DISCUSSION**

Improvements in signs/symptoms, physical function, range of motion and HRQoL achieved at week 241 and sustained through week 268 of GO-RAISE were also sustained with up to 5 years of golimumab treatment of patients with AS. While findings were generally similar between the golimumab doses, this is the first report to assess the effects of a dose increase in patients with AS who had inadequate response to golimumab 50 mg. When investigators were allowed to increase the dose in consultation with their patients for lack of efficacy, 61% of patients gained ASAS20 response. While the golimumab dose approved for the treatment of active AS is 50 mg, this is an important finding that reflects a scenario likely to be encountered in clinical practice. Results of the recently published certolizumab trial in axial spondyloarthritis, which compared the same cumulative dose given at two different dosing intervals (200 mg every 2 weeks and 400 mg every 4 weeks), indicated very similar efficacy.13 Thus, to our knowledge, GO-RAISE is the only large prospective trial of a TNF-inhibitor in AS comparing two different doses and showing a dose response in patients who have inadequate response to the lower dose. Similar findings have been reported in patients with rheumatoid arthritis.14

Approximately a fifth of the 255 patients who participated in the long-term extension did not achieve an ASAS20 response at 5 years, yet they continued to receive golimumab and completed the trial, which is consistent with results observed through...
improved performance-based physical function in ASAS20 non-
agents, suggest that there is apparent bene
of treatment. Our results, as well as those observed with other
on one outcome measure, plus expert opinion, for continuation
These recommendations include assessment of response based
the expected minimal therapeutic response for such agents have
ment with TNF-inhibitors can be costly, recommendations on
was enough for them to elect study continuation. Since treat-
pain, and sleep improvement, their cumulative improvement
as deriving <20% relief in their night-time pain, overall back
a different level of improvement acceptable to continue that
improvement in symptoms is the lowest level acceptable to a
clinician to indicate ef
cacy , an individual patient may consider

>3 years of etanercept14 and 5 years of adalimumab15 in
patients with AS. Thus, while ASAS20 response is a validated
composite measure of patient outcome, it may not include all
aspects of improvement important to patients. Also, while 20%
improvement in symptoms is the lowest level acceptable to a
clinician to indicate efficacy, an individual patient may consider
a different level of improvement acceptable to continue that
therapy. Indeed, we determined that even though these patients
were deriving <20% relief in their night-time pain, overall back
pain, and sleep improvement, their cumulative improvement
was enough for them to elect study continuation. Since treat-
mant with TNF-inhibitors can be costly, recommendations on
the expected minimal therapeutic response for such agents have
been published by independent organisations such as ASAS.
These recommendations include assessment of response based
on one outcome measure, plus expert opinion, for continuation
of treatment. Our results, as well as those observed with other
agents, suggest that there is apparent benefit, including
improved performance-based physical function in ASAS20 non-
responders, experienced by patients that is not captured by a
single measure.15–17 Hence, other tertiary end points or patient-
reported outcomes should be considered in future research of
treatment persistence.

The golimumab safety profile through week 268 was consistent
with those previously reported.1,2 Importantly, no increases in
serious AEs, malignancies, serious infection or injection-site reac-
tions were observed in successive years of golimumab treatment.

While efficacy analyses were performed using a conservative
ITT approach, and consistency was observed between the ITT and
observed data analyses, the findings reported here remain limited
by several factors. It is important to note that no patients received
placebo, and thus there is no control group, after week 24. Also,
the study was blinded through the week 100 database lock, but
open label from that point forward. Changes to the golimumab
open label from that point forward. Changes to the golimumab

Table 1  Summary of AEs through week 268

<table>
<thead>
<tr>
<th></th>
<th>GLM 50 mg only</th>
<th>GLM 50 mg and 100 mg</th>
<th>GLM 100 mg only</th>
<th>All GLM patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>158</td>
<td>77</td>
<td>118</td>
<td>353</td>
</tr>
<tr>
<td>Mean weeks of follow-up</td>
<td>207.6</td>
<td>232.2</td>
<td>213.0</td>
<td>214.8</td>
</tr>
<tr>
<td>Pts with AE(s)</td>
<td>153 (96.8%)</td>
<td>76 (98.7%)</td>
<td>115 (97.5%)</td>
<td>344 (97.5%)</td>
</tr>
<tr>
<td>Pts who died</td>
<td>1 (0.6%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs*</td>
<td>0.16</td>
<td>0.00</td>
<td>0.00</td>
<td>0.07</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.00 to 0.88)</td>
<td>(0.00 to 0.87)</td>
<td>(0.00 to 0.62)</td>
<td>(0.00 to 0.38)</td>
</tr>
<tr>
<td>Pts with serious AE(s)</td>
<td>27 (17.1%)</td>
<td>19 (24.7%)</td>
<td>26 (22.0%)</td>
<td>72 (20.4%)</td>
</tr>
<tr>
<td>Pts who discontinued AE(s)</td>
<td>12 (7.6%)</td>
<td>6 (7.8%)</td>
<td>14 (11.9%)</td>
<td>32 (9.1%)</td>
</tr>
<tr>
<td>Pts with malignancy t</td>
<td>1 (0.6%)</td>
<td>1 (1.3%)</td>
<td>1 (0.8%)</td>
<td>3 (0.8%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs</td>
<td>0.16</td>
<td>0.29</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.00 to 0.88)</td>
<td>(0.01 to 1.63)</td>
<td>(0.01 to 1.16)</td>
<td>(0.04 to 0.60)</td>
</tr>
<tr>
<td>SIR—observed/SEER</td>
<td>0.58</td>
<td>0.00</td>
<td>0.00</td>
<td>0.21</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.01 to 3.21)</td>
<td>(0.00 to 1.77)</td>
<td>(0.00 to 2.37)</td>
<td>(0.01 to 1.19)</td>
</tr>
<tr>
<td>Lymphoma t</td>
<td>1 (0.6%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs</td>
<td>0.16</td>
<td>0.00</td>
<td>0.00</td>
<td>0.07</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.00 to 0.88)</td>
<td>(0.00 to 0.87)</td>
<td>(0.00 to 0.62)</td>
<td>(0.00 to 0.38)</td>
</tr>
<tr>
<td>SIR—observed/SEER</td>
<td>9.67</td>
<td>0.00</td>
<td>0.00</td>
<td>3.80</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.24 to 53.90)</td>
<td>(0.00 to 35.60)</td>
<td>(0.00 to 39.68)</td>
<td>(0.10 to 21.18)</td>
</tr>
<tr>
<td>NMSC5</td>
<td>0 (0.0%)</td>
<td>1 (1.3%)</td>
<td>1 (0.8%)</td>
<td>2 (0.6%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs</td>
<td>0.00</td>
<td>0.29</td>
<td>0.21</td>
<td>0.14</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.00 to 0.47)</td>
<td>(0.01 to 1.63)</td>
<td>(0.01 to 1.16)</td>
<td>(0.02 to 0.50)</td>
</tr>
<tr>
<td>Other malignancies t</td>
<td>1 (0.6%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs</td>
<td>0.16</td>
<td>0.00</td>
<td>0.00</td>
<td>0.07</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.00 to 0.88)</td>
<td>(0.00 to 0.87)</td>
<td>(0.00 to 0.62)</td>
<td>(0.00 to 0.38)</td>
</tr>
<tr>
<td>SIR—observed/SEER</td>
<td>0.61</td>
<td>0.00</td>
<td>0.00</td>
<td>0.22</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.02 to 3.39)</td>
<td>(0.00 to 1.85)</td>
<td>(0.00 to 2.52)</td>
<td>(0.01 to 1.25)</td>
</tr>
<tr>
<td>Pts with serious infection(s)</td>
<td>6 (3.8%)</td>
<td>8 (10.4%)</td>
<td>7 (5.9%)</td>
<td>21 (5.9%)</td>
</tr>
<tr>
<td>Incidence100 pt-yrs**</td>
<td>1.27</td>
<td>3.49</td>
<td>2.28</td>
<td>2.13</td>
</tr>
<tr>
<td>(Exact 95% CI)</td>
<td>(0.55 to 2.50)</td>
<td>(1.80 to 6.10)</td>
<td>(1.14 to 4.07)</td>
<td>(1.44 to 3.02)</td>
</tr>
<tr>
<td>Pts with injection-site reaction(s)</td>
<td>17 (10.8%)</td>
<td>13 (16.9%)</td>
<td>13 (11.0%)</td>
<td>43 (12.2%)</td>
</tr>
</tbody>
</table>

Data presented are n (%) unless indicated otherwise.
*Incidence/100 pt-yrs (Exact 95% CI) of death for placebo through week 24=0.00 (0.00 to 10.42).
†Incidence/100 pt-yrs (Exact 95% CI) of all malignancies for placebo through week 24=3.50 (0.09 to 19.48); SIR (Exact 95% CI)=0.00 (0.00 to 33.37).
‡Incidence/100 pt-yrs (Exact 95% CI) of lymphoma for placebo through week 24=0.00 (0.00 to 10.42); SIR (Exact 95% CI)=0.00 (0.00 to 382.38).
§Incidence/100 pt-yrs (Exact 95% CI) of NMSC for placebo through week 24=3.50 (0.09 to 19.48).
¶Incidence/100 pt-yrs (Exact 95% CI) of other malignancies for placebo through week 24=0.00 (0.00 to 10.42); SIR (Exact 95% CI)=0.00 (0.00 to 35.60).
‖Incidence/100 pt-yrs (Exact 95% CI) of all malignancies for placebo through week 24=3.50 (0.09 to 19.48); SIR (Exact 95% CI)=0.00 (0.00 to 33.37).
**Incidence/100 pt-yrs (Exact 95% CI) of serious infections for placebo through week 24=3.48 (0.09 to 19.39).
AE, adverse event; GLM, golimumab; NMSC, non-melanoma skin cancer; n.e., number; pts, patients; pt-yrs, patient-years; SEER, Surveillance, Epidemiology and End Results database; SIR, standardised incidence ratio.
Acknowledgements The authors thank the patients, the investigators and the study personnel who made this trial possible. The authors also thank Michelle Perate and Mary Whitman of Janssen Scientific Affairs, medical writers who helped draft, collate author comments for, collect approvals for, and submit the manuscript.

Funding This study was supported by Janssen Research & Development, and Merck/Schering-Plough Research Institute.

Competing interests JB has received honoraria for talks, advisory boards and grants for studies from Celltrion, Amgen, Abbott, Roche, BMS, Janssen, Novartis, Pfizer (Wyeth), MSD (Schering-Plough), Sanofi-Aventis and UCB. AD has received payments for educational lectures, teleconferences and serving on advisory boards for Janssen. This potential conflict of interest has been reviewed and managed by OHSU. RDI has received consulting fees from Merck, Schering-Plough, Abbott, Amgen and Sanofi-Aventis. DvDH has received funding from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Chugai, Covagen, Daiichi, Eli-Lilly, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB and Vertex and is Director of Imaging Rheumatology BV. YZ, SX, CH and BH are employees of Janssen R&D, a Johnson & Johnson pharmaceutical company, and own stock and/or stock options in Johnson & Johnson.

Ethics approval Approved by the Institutional Review Board/Independent Ethics Committee Governing each site.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/